Hasil Pencarian (1)
small molecule | CAS: 2326521-71-3
Adagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.[A254941] However, the development of KRAS inhibitors has …
Kategori:
Antineoplastic AgentsAntineoplastic Agents, ImmunologicalAntineoplastic and Immunomodulating Agents
+21
Target Protein:
GTPase KRas
Waktu ParuhAdagrasib has a ter…
Vol. DistribusiAdagrasib has an ap…
KlirensAdagrasib has an ap…
Genetik
-